Dr. Siegall, Clay Chief Executive Officer, and Co-founder of Seattle Genetics

Dr. Siegall Clay is the current serving CEO, President, and Co-founder of Seattle Genetics. He has worked in different research institutes and organizations, before co-founding Seattle Genetics. He attained his B.S in Zoology from Maryland University, and later on a Ph.D. specializing in Genetics from George Washington University. He also serves on the board of Directors in two different private companies, Mirna Therapeutics, and Alder Biopharmaceuticals. He kicked off his career serving at National Institutes of Health from the year 1988 to 1991 and later worked at Bristol-Myers Squibb pharmaceutical Research Institute from the year 1991 to 1997.

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

Seattle Genetics was founded in the year 1998, with Dr. Siegall as the President. The company is a biotechnology company that works on developing preclinical and clinical products, and research that is devoted to Cancer research. The company has earned good reputation over the years as the leading antibody technologies. His leadership has helped the company attain numerous strategic licenses with its technology. The licenses include Abvie, Pfizer, and Genentech (Roche), generating over 300$ million Dollar in revenue, since its inception. Seattle Genetics technology has earned and maintained a huge share in the clinical development programs, having over 20 ADCs in the development of clinical products all across the program.

Prior to Seattle Genetics getting numerous collaborations, the company achieved an exclusive international strategic collaboration agreement with Genentech worth over $860 million for SGN-40. The ADCs technology is designed to not affect non-targeted cells. It has worked to reduce the numerous side effects that came with the traditional Chemotherapy but also maintaining high antitumor activity. The company leads in ADCs with their program ADCETRIS (brentuximab vedotin), which opened a new class in the ADCs technologies. Not only is the program broad and recommended for clinical development programs but also runs a huge potential of soon becoming the foundation for treatment of Hodgkin Lymphoma, B-cell lymphomas, CD-30 expressing lymphomas, and B-cell lymphomas.

The collaboration with Takeda helped Seattle Genetics achieve full rights with its ADCETRIS program in both Canada and the United States. Takeda has the upper hand in the commercialization rights, maintaining them exclusively in all other countries.

Leave a Reply

Your email address will not be published. Required fields are marked *